Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Feliza Mirasol is the science editor for 

Articles

Under the partnership, Pharmaron will validate and promote the application of CN Bio’s PhysioMimix technology and will integrate OOC technologies into its R&D platform.

CN Bio Forms Strategic Partnership with Pharmaron to Develop OOC Technologies 

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Boehringer Ingelheim Previews New Product Launches Expected in 2025

The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.

PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Videos

Pharmaceutical Technology® Group spoke with Erik Wiklund, CEO of Circio, about the future of M&A in the bio/pharmaceutical industry and the struggle small biotech companies face raising funds.

Industry Outlook 2025: Mergers, Acquisitions, and Funding

The commitment will include new, state-of-the-art R&D facilities as well as new or expanded manufacturing sites in multiple states.

Roche to Invest $50 Billion in US Pharmaceuticals and Diagnostics

The PharmTech Group interviewed Edwin Stone, CEO of Cellular Origins, about the impact of the changing political landscape on the pharmaceutical industry.

Industry Outlook 2025: The Impact of Politics on Pharma

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Mike Exton, Andrew Thomson, Konstantinos Tsioris, and Cheryl Barton go behind the headlines to discuss the advancement of neuroscience, weight-loss drugs, and the evolving political climate’s impact on the industry.

Behind the Headlines Episode 15–Neuroscience, Weight-Loss Drugs, and Tariffs

Vitrakvi (larotrectinib) was first granted accelerated approval by FDA in November 2018.

Bayer Announces FDA’s First Full Approval of NTRK Inhibitor

Pharmaceutical Technology® spoke with Alexander Seyf, CEO and co-founder of Autolomous, about the use of artificial intelligence and machine learning in pharmaceutical development and manufacturing.

Industry Outlook 2025: Technology as a Supporting Element

The company has plans to invest $23 billion during the next five years to expand manufacturing and R&D in the US, which will include seven new facilities.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development